Skip to content

13F-HR filed by Saturn V Capital Management LP

Saturn V Capital Management LP filed this 13F-HR for the quarter ended 2026-09-30, accepted by EDGAR 2026-11-16 17:33:11 UTC, with 24 holding rows worth $683,127,656.

Accession
0001964437-26-000015
Filed
2026-11-16
Accepted by EDGAR
Ingested
Source
EDGAR live feed

Original filing

13F report for Q3 2026

A holdings report, 24 entries on the cover page, a total value of $683,127,656 stated on the cover page (in dollars after the unit check, H1), rows summing to $683,127,656 with VALUE read as dollars as filed, 13F file number 028-22863. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
AMYLYX PHARMACEUTICALS INC03237H101COM4,471,356$130,116,460dollars as filed
ABIVAX SA-00370M103SPONSORED ADS529,313$52,412,573dollars as filed
IMMIX BIOPHARMA INC45258H106COMMON STOCK4,661,115$48,498,902dollars as filed
PHARVARIS NVN69605108COMMON STOCK1,393,956$44,216,284dollars as filed
VAXCYTE INC COM92243G108Stock772,258$43,941,480dollars as filed
CELCUITY INC15102K100COM513,847$40,861,113dollars as filed
DISC MEDICINE INC COM254604101Stock612,661$40,104,789dollars as filed
CANDEL THERAPEUTICS INC137404109COMMON STOCK3,476,206$36,291,591dollars as filed
JAZZ PHARMACEUTICALS PLC SHS USDG50871105Stock150,340$34,806,717dollars as filed
MONOPAR THERAPEUTICS INC61023L207COMMON STOCK312,350$24,884,924dollars as filed
VIR BIOTECHNOLOGY INC92764N102COM2,040,422$22,811,918dollars as filed
TREVI THERAPEUTICS INC COM89532M101Stock1,573,876$22,537,904dollars as filed
X4 PHARMACEUTICALS INC98420X202COMMON STOCK7,366,442$21,362,682dollars as filed
ALUMIS INC022307102COM2,855,811$21,104,443dollars as filed
SAGIMET BIOSCIENCES INC A786700104COMMON STOCK2,002,813$19,787,792dollars as filed
DYNE THERAPEUTICS INC COM26818M108Stock837,175$13,486,889dollars as filed
ALTO NEUROSCIENCE INC COM SHS02157Q109Stock518,109$13,227,323dollars as filed
ULTRAGENYX PHARMACEUTICAL IN90400D108COM758,771$11,404,328dollars as filed
ZURA BIO LTDG9TY5A101COMMON STOCK2,032,454$8,455,009dollars as filed
INHIBIKASE THERAPEUTICS INC45719W205COMMON STOCK3,869,056$7,950,910dollars as filed
OCULIS HOLDING AGH5870P102CMN847,444$7,915,127dollars as filed
ERASCA INC COM29479A108Stock514,309$7,539,770dollars as filed
Latigo Biotherapeutics, Inc.517954103Common Stock, par value $0.0001 per share300,355$5,015,928dollars as filed
SATELLOS BIOSCIENCE INC80401L803COM516,800$4,392,800dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001964437-26-000015this filing2026-11-16